Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
MADISON, Wis., May 30, 2017 -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6 at 12:00 Noon PT/3:00 PM ET. Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.
The LD Micro Invitational conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles and will feature 180 companies in the small/micro-cap space.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 clinical study in patients with relapsed or refractory multiple myeloma. In addition, the company has initiated a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit www.cellectar.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]
